Scientific poster: Developing protein: Protein Interaction (PPI) assays with AlphaLISA and LANCE TR-FRET
In this scientific poster, PerkinElmer demonstrates the ease and utility of using AlphaLISA® and LANCE® TR-FRET homogenous assay forms for studying PPIs.
Protein: protein interactions (PPIs) are central to the molecular processes that take place within a cell, as the function of any given protein is often regulated by other proteins. In recent years, modulation of PPIs has received increased attention in the scientific community as a whole, and specifically within the realm of drug discovery. PPIs are being studied as therapeutic targets in a variety of diseases including cancer, cardiovascular disease, and even HIV.
Currently, there are a variety of methods used to detect PPIs, each with its own strengths and weaknesses. This is especially true in regards to sensitivity and specificity. However, the ideal assay is a cell-based, homogenous assay that maintains both its specificity and sensitivity.
Here we show that both the AlphaLISA and LANCE TR-FRET technologies allow for the development of protein: protein interaction assays in cell-based, homogenous no-wash formats suitable to HTS applications.
This scientific poster is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Related content from this organisation
- Webinar highlights: Harmonising drug-target binding data analytics on a single platform
- Webinar preview: Compliance with data integrity and computerised system validations
- Harmonising drug-target binding data analytics on a single platform
- Compliance with data integrity and computerised system validations
- Assays In-Depth Focus 2018